CATHY SEIPP ON BLUE CROSS: “To decide after a therapy has proved beneficial that it’s merely ‘investigational’ and therefore should not be covered — that, actually, seems the definition of bad faith. . . . What I didn’t realize at the time was that I’d turn out to be my insurance company’s worst nightmare — the cancer patient who keeps responding to extremely expensive treatments. I only hope that Blue Cross doesn’t turn out to be mine.”